Abstract
91 Patients with advanced breast cancer failing adriamycin (ADR)-containing combination chemotherapy were treated with a combination of mitomycin C (MMC) and megestrol acetate. Congestive heart failure (CHF) occurred in 14 (15.3%) of 91 MMC-treated patients compared to three (3.4%) of 89 patients treated with similar ADR-containing combination chemotherapy without MMC (P=0.01). The median time from the last dose of ADR to evidence of CHF was 8.5 months for the MMC group compared to 1.5 months for the other group. A significantly higher incidence of late onset of CHF implicates MMC as a possible cardiotoxic agent.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1005-1008 |
| Number of pages | 4 |
| Journal | American Surgeon |
| Volume | 62 |
| Issue number | 7 |
| State | Published - 1978 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Adriamycin and mitomycin C: Possible synergistic cardiotoxicity'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS